> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# DelMar Pharma Gets Orphan Drug for Ovarian Cancer
- URL: https://www.fdaweb.com/delmar-pharma-gets-orphan-drug-for-ovarian-cancer/
- Published: 2016-04-21T12:00:00.000Z
- Updated: 2026-09-14T20:56:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135457

FDA’s Office of Orphan Products Development has granted orphan drug designation to DelMar Pharmaceuticals for its first-in-class small-molecule chemotherapeutic VAL-083 to treat ovarian cancer. According to the company, in over 40 Phase 1 and 2 clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single agent and in combination with other treatments. It says FDA previously granted orphan drug designation for glioma and medulloblastoma.